From: Tegeris, John (OS/ASPR/BARDA) (CTR) [john.tegeris@hhs.gov]

Sent: 5/4/2017 8:52:13 PM

To: Bright, Rick (OS/ASPR/BARDA) [Rick.Bright@hhs.gov]; Disbrow, Gary (OS/ASPR/BARDA) [Gary.Disbrow@hhs.gov];

Schafer, Julie (OS/ASPR/BARDA) [Julie.Schafer@hhs.gov]; Maher, Carmen (FDA/OC) [Carmen.Maher@fda.hhs.gov]; Sadove, Elizabeth (FDA/OC) [Elizabeth.Sadove@fda.hhs.gov]; Ross, Jennifer (FDA/OC) [Jennifer.Ross@fda.hhs.gov]; Nalubola, Ritu (FDA/OC) [Ritu.Nalubola@fda.hhs.gov]; Flamm, Eric (FDA/OC) [Eric.Flamm@fda.hhs.gov]; Zborowsky,

Ashley (FDA/OC) [Ashley.Zborowsky@fda.hhs.gov]; Epstein, Laura (FDA/CVM) [Laura.Epstein@fda.hhs.gov]; Hartman, Mark [Hartman.Mark@epa.gov]; McNally, Robert [Mcnally.Robert@epa.gov]; Mendelsohn, Mike

[Mendelsohn.Mike@epa.gov]; Milewski, Elizabeth [Milewski.Elizabeth@epa.gov]; Wozniak, Chris

[wozniak.chris@epa.gov]; Jennings, Susan [Jennings.Susan@epa.gov]; Layne, Arnold [Layne.Arnold@epa.gov]; Rosenblatt, Daniel [Rosenblatt.Dan@epa.gov]; Petersen, Lyle (CDC/OID/NCEZID) [lxp2@cdc.gov]; Beard, Charles (Ben) (CDC/OID/NCEZID) [cbb0@cdc.gov]; Koonin, Lisa (CDC/OID/NCIRD) [lmk1@cdc.gov]; Kovacs, Gerald (OS/ASPR/BARDA) (CTR) [Gerald.Kovacs@hhs.gov]; Seals, Jonathan (OS/ASPR/BARDA) [jonathan.seals@hhs.gov];

Craven, Mark (OS/ASPR/BARDA) [Mark.Craven@hhs.gov]; Knight, Antoinette (OS/ASPR/BARDA)

[Antoinette.Knight@hhs.gov]; Costero-Saint Denis, Adriana (NIH/NIAID) [E] [acostero@niaid.nih.gov]; Leissa, Brad G (FDA/CDER) [Brad.Leissa@fda.hhs.gov]; Lueptow, Rebekka (HHS/ASPR/BARDA) [Rebekka.Lueptow@hhs.gov]; Wolf, Laura (OS/ASPR/OEM) [Laura.Wolf@hhs.gov]; Curren, Stephen (OS/ASPR/OEM) [Stephen.Curren@hhs.gov]; Erlandson, Karl (OS/ASPR) [Karl.Erlandson@hhs.gov]; JBobo@intrexon.com; hutchinsont@gtlaw.com; Simon Warner

(Simon.Warner@oxitec.com) [Simon.Warner@oxitec.com]; Little, James (OS/ASPR/BARDA) [James.Little@hhs.gov]

Subject: Interagency Meeting with Oxitec/Intrexon Group; Wed May 17, 10am-12pm ET

Location: BARDA HQs, O'Neill Bldg, 200 C Street, DC, SW, Elm Conf Rm (2nd Flr)

Start: 5/17/2017 2:00:00 PM **End**: 5/17/2017 4:00:00 PM

Show Time As: Tentative

Recurrence: (none)

Hi All,

Hope everyone is doing well. As promised, this serves as the formal invite for our interagency meeting with the Oxitec/Intrexon group here at BARDA HQs (O'Neill Building; 200 C Street, SW) on Wed May 17 from 10am-12pm ET (Elm Conference Room, 2nd floor). Please let me know if you will be attending in person so we can manage security/clearance logistics (we would be grateful for a good turnout in person, so thanks for accommodating if at all possible). For those attending remotely, we will either have Webex capabilities or will forward along any slide presentations/materials in advance of the meeting. For those arriving by Metro, the closest stop is the Orange/Blue Lines and Federal Center Southwest stop (we will be sure to have help on hand to clear you through security and escorted up to Elm, for those that require check in). Dial-in numbers with international capability are listed further below.

We are pleased to have assembled such a strong group across agencies with deep expertise to help guide the discussions with the Oxitec/Intrexon team. We have asked Oxitec/Intrexon colleagues to prepare a slide deck to present at the start of the meeting to outline the current situation and guide the discussion with all the right experts gathered together in one place, which will allow us to better address their specific questions. It is our hope that by the end of the meeting there is even more clarity on the path forward and a faster way to get there given the pressing challenges they face along the regulatory pathway and for conducting the all-important POC field study. Also, please feel free to forward along this invite to others within your respective groups that have a need or interest to attend.

Ex. 6 - Personal Privacy

We look forward to seeing you all on May 17. Easy to reach anytime for follow up on cell 301-996-5102. Much appreciated!

Best, John